RDPAC Says Fees To Gather Phase IV Clinical Data Not Bribes
This article was originally published in PharmAsia News
Executive Summary
RDPAC has requested to the China FDA not to consider paying doctors for collecting post-marketing phase IV clinical data as bribery, citing it as crucial for data integrity.